Clinical Trials
36 trialsA Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
A Phase I Study of BR108 in Hematological Malignancies
BioRay Pharmaceutical Co., Ltd.
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hangzhou Sumgen Biotech Co., Ltd.
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
Fred Hutchinson Cancer Center
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Gilead Sciences
CYNK001AML01
Celularity Incorporated
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
Fred Hutchinson Cancer Center
ERASER
Antengene Corporation
ATRIUM
Antengene Corporation
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AstraZeneca
Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
AbbVie
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
SecuraBio
Study of IV CBL0137 in Previously Treated Hematological Subjects
Incuron
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
University of Chicago
Japanese AML
Gilead Sciences
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
ABC123
Cellectis S.A.
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
M.D. Anderson Cancer Center
Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers
Washington University School of Medicine
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
Fate Therapeutics
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
University Health Network, Toronto
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
H. Lee Moffitt Cancer Center and Research Institute
Dose Escalation of IPI-493 in Hematologic Malignancies
Infinity Pharmaceuticals, Inc.
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sanofi
Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
National Cancer Institute (NCI)
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer
Myriad Therapeutics, Inc.